eShowcase: GlobalView EventNet
System enables IRB members to review ?s in near real-time from anywhere in the world
System enables IRB members to review AEs in near real-time from anywhere in the world
GlobalView EventNet
PPD, Inc. (Wilmington, NC) just released a customizable, global event management and adjudication system for quick review of safety and endpoint-driven data from large clinical trials or registries. The secure, Internet-based system provides broad access to adverse event data, particularly in studies with multiple information sources and ones that need review by a board of independent physicians.
GlobalView EventNet provides access to data in near real-time and allows IRB members to examine the data at their own convenience from any location around the world. The board members can also request follow-up information or confirm adjudicated events through an online interface. GlobalView EventNet also sends automatic email alerts to prompt and encourage timely review. The system electronically compares each IRB member's decision and documents them per established guidelines.
PPD, Inc., (910) 251-0081, www.ppdi.com
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
